First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
Clinical trial NCT06070740 · RECRUITING
Trial details
- NCT number
- NCT06070740
- Sponsor
- Peking Union Medical College Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-01
- Primary completion
- 2026-11-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.